We examined the possibility of changes in gene expression of the NMDA receptor subunits after chronic antagonist treatment. Exposure of neurons to the NMDA antagonist
nist; mRN4 subunit; immunoblot; upregulation; neuronal cell culture
The NMDA receptor (NMDAR), a subtype of glutamate receptors, is an oligomeric ligand-gated ion channel complex formed by the assembly of different subunits (Monyer et al., 1992) . This receptor contains distinct recognition sites for endogenous and exogenous ligands, such as glutamate, glycine, Mg'+, Zn*+, polyamines, and open-channel blockers such as MK-801 (Mayer and Westbrook, 1987; Collingridge and Lester, 1989; Watkins et al., 1990) . Recent studies have demonstrated that the various NMDAR subunits may be subjected to differential regulation during development and by various ligands that modulate this receptor complex (Pujic et al., 1993; Riva et al., 1994; Sheng et al., 1994; Watanabe et al., 1994; Zhong et al., 1994; Follesa and Ticku, 1995) . The functional properties of the NMDAR can be modulated by the presence of different NMDAR subunit types (Anantharam et al., 1992; Monyer et al., 1992) . The NMDARs are thought to be involved in processes such as memory and learning, neuronal developmental plasticity, epileptogenesis, and in some forms of acute and chronic neuropathologies (Mayer and Westbrook, 1987; Choi, 1988; Collingridge and Lester, 1989) . NMDAR antagonists can protect against excitotoxicity in vivo (McDonald et al., 1990) and in vitro (Choi, 1988; Goldberg et al., 1988) . Based on these lines of evidence, the NMDAR antagonists could be useful therapeutic agents in the treatment of ischemic brain injury and certain neurological dysfunctions, such as epilepsy and neuronal degeneration, which may involve excessive glutamatergic transmission. (Choi, 1988; Albers et al., 1989; Muir and Lees, 19%) .
One of the unwanted effects of chronic treatment with drugs, including receptor antagonists, is the development of pharmacodynamic tolerance (Aarons et al., 1980; Jenner and Marsden, 1983) . The molecular mechanism(s) underlying this phenomenon have yet to be elucidated. There is evidence that treatment with the NMDAR antagonists, in viva and in cell culture, leads to upregulation of the NMDA receptors, as measured by radioligand-binding studies (McDonald et al., 1990; Williams et al., 1992) . However, it is not known whether an increase in binding corresponds to a real increase in the protein and mRNA expression, or whether other mechanisms are involved in this phenomenon.
Furthermore, oligomeric receptors such as the NMDAR, composed by different subunits, are derived from different genes (Moriyoshi et al., 1991; Monyer et al., 1994) ; it is not known whether all the genes encoding the diverse subunits are equally or differentially regulated in response to a particular treatment.
The use of animals to study the effect of antagonists on the NMDAR is not always desirable. Primary neuronal cell cultures provide a useful model to study the pharmacology and the molecular phenomenon that may be related to the regulation of the NMDAR expression. In the present study, we tested the hypotheses that the upregulation of the NMDAR complex observed after chronic antagonist exposure may be attributable to an increase in the mRNA and polypeptide expression of the different NMDAR subunits.
MATERIALS AND METHODS
cDNA p~el,at~~fion. The primer pairs (scqucnccs puhlishcd in Follesa and Ticku, 1995) wcrc dcsigncd to include cDNA scqucnces with the lowest dcgrcc of homology bctwccn the mRNA of the different mouse NMDA receptor subunits R2A, R2B, and R2C, as described previously for the rat (Follcsa and Ticku, 1995) by trituration using a Pasteur pipette as described previously (Hu et al., 1996) . Dissociated cells were counted under a microscope using a hcmocytometer, and the trypan blue stain method was used to determine the number of viable cells. Cells were resuspended in the culture medium to have 2 X 10" cells/ml, and 12 ml of this cell suspension were used for each poly-L-lysine-coated 75 cm* plastic flasks. The cells were grown in Minimum Essential Medium (MEM) containing 33.3 mM glucose, 26.2 mM NaHCO,, 100 pM L-glutamine, 10% fetal bovine serum (FBS), and 10% horse serum (MEM lO/lO) in an incubator with 95% 0,/5% CO, at 37°C. The concentration of L-glutamine used in the present study was 100 FM as opposed to 2 mM used in a previous study (Hu and Ticku, 19Y5) . This variation in experimental conditions is justified by the fact that a conccntration of 2 mM glutamine produces high concentrations of glutamate (Hamilton, 1945) . In one pilot experiment, the concentration of glutamate was measured (495 ? 35 FM; II = 3) iI the 2 IIIM L-g~Ul~UIIillC-containing media using a glutamine-glutamate determination kit (Sigma, St. Louis, MO).
This high concentration of glutamate prcvcnted the o( -)-2-amino-5-phosphonopentanoic acid (AP-5).induced upregulation of the NMDARs (see Results). Because the expression of the NMDAR subunit mRNA depends on the concentration of FBS in the media (Zhong et al., 1994; Follesa and Ticku, unpublished observations), the media was substituted with MEM containing 5% FBS plus 5% horse serum (MEM/lO) on the second day in culture. In addition, on the second day in culture a mixture of 5-fluoro-2'.deoxyuridine and uridine at a final concentration of 10 pg/ml was added to the media to inhibit cell proliferation (Godfrey et al., 1975 values were normalized by dividing the number of counts per minute of each protected fragment band of the different NMDA receptor subunits by the number of counts per minute of each protected fragment band of the cyclophilin, and expressing the amount of mRNA in arbitrary units (ratio between counts per minute).
For the immunoblot experiments, the relative changes in expression of polypeptides were calculated estimating the intensity of the band with National Institutes of Health IMAGE system. The data were normalized to the amount of proteins loaded in each lane in the Coomassie bluestained gel that was run in parallel by measuring both the major band of -58 kDa (see Fig. 5c ) and the intensity of the whole lane. We performed pilot studies in which different amounts of protein (lo-60 pg) were loaded on the gel with the antibodies used in the present study, and we observed that the intensity of the bands was in the linear range for both 
RESULTS
Expression of NMDAR subunit mRNA in cultured mouse cortical neurons Figure 1 shows the relative levels of mRNA for the three different subunits of the NMDAR complex at days 3, 5, and 7 in cultured cortical neurons that exhibited the following rank order: R2B > Rl > R2A. The R2C subunit mRNA was not expressed in this cell culture preparation (Fig. 2) .
Prolonged AP-5 exposure selectively upregulates NMDAR R2B mRNA subunit
Our initial experiments were performed using the 2 mM glutamine-containing medium. Under these conditions, exposure of the cells to AP-5 (100 pM; 5 d) did not upregulate the R2B mRNA subunit (Fig. 3) . All the subsequent experiments were performed using a concentration of 100 PM glutamine as described in Materials and Methods. Under these conditions, exposure of the neurons to the competitive NMDAR antagonist AP-5 for 5 d selectively increased the mRNA levels of the R2B subunit (45%) without altering the levels of mRNA encoding for the Rl and R2A subunits (Fig. 2, Table 1 ). This effect was concentrationdependent (Fig. 4A) . Using concentrations ranging from 10 to 500 pM, we observed a maximum increase of mRNA encoding for the R2B subunit at 100 PM (5 d). The NMDAR R2B subunit mRNA upregulation was also time-dependent (Fig. 4B) , and the peak increase was observed after 5 d exposure. Longer exposure (up to 7 d) produced the same effect as 5 d exposure (data not shown), so for subsequent experiments we used a concentration of 100 PM AP-5 for 5 d. The observed upregulation was reversible, because 48 hr removal of the antagonist returned the R2B subunit mRNA to the control levels (data .not shown).
Concomitant exposure of AP-5 (100 PM; 5 d) and NMDA (1 mM; 5 d) was able to reverse the AP-5-mediated upregulation of the NMDAR (Table 1) . Chronic exposure of the cortical neurons to the NMDA receptor open-channel blocker MK-801 (1 PM; 5 d) also produced an increase (40%) in the R2B mRNA subunit (Table 1 ). In contrast, chronic exposure (10 PM; 5 d) to the non-NMDAR antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX)
did not produce upregulation of any of the NMDAR mRNA subunits (Table 1) .
AP-&mediated upregulation of the NMDAR polypeptides
To further characterize the AP-5-mediated upregulation of the NMDAR complex, we wanted to verify whether an increase in mRNA expression corresponded to a concomitant increase in the NMDAR subunit polypeptide (using the concentration of 100 PM for 5 d that gives the maximal response). We immunodetected the NMDAR polypeptide subunits using the AB1548 antibody [which recognized the R2AIB subunit and gives a single band of 165 kDa (Fig. 5a) ] and the AB1516 antibody [which recognized the Rl subunit and gives a single band of 116 kDa (Fig. 5b) J. We found that 5 d exposure to the NMDAR antagonist AP-5 (100 PM) produced a 60-70% increase in the levels of the Rl subunit polypeptide (Fig. 5, Table 2 ) without altering the mRNA levels of this subunit (Table 1) . We also observed a fivefold increase in the levels of the R2 subunit polypeptides in the AP-5-treated cells compared with control cells. MK-801 (1 PM; 5 d) produced a similar effect as AP-5 (100 PM; 5 d) (Table 2) , and the non-NMDAR antagonist CNQX (10 FM; 5 d) had no effect on the NMDAR expression (Fig. 5, Table 2 ). The effect of AP-5 was reversed by concomitant exposure of NMDA (1 mM; 5 d) (Fig. 5, Table 2 ). Lower concentration of NMDA (100 PM; 5 d) did not block the AP-5-mediated increase in NMDAR polypeptide subunits (Table 2). Cells treated with NMDA (1 mM; 5 d) alone did not show any morphological differences (data not shown) or changes in the NMDAR polypeptide expression with respect to control cells (Table 2) . These results are in agreement with the results obtained in the experiments in which high concentrations of glutamine and glutamate were present in the media (Fig. 3) .
DISCUSSION
The use of NMDAR antagonists as potential therapeutic agents to diminish or ameliorate the progression of degenerative diseases or syndromes in which glutamatergic transmission may be involved has been proposed (Choi, 1988) antagonists are currently in clinical trials (Muir and Lees, 1995) . However, chronic treatment with receptor antagonists can lead to an increased density of receptors that may complicate the therapeutic efficacy of such drugs (Aarons et al., 1980; Jenner and Marsden, 1983; McDonald et al., 1990) . It has been demonstrated that treatment with the NMDAR antagonists produces an upregulation of the NMDAR complex in viva and in cortical cultures as measured by an increase in the B,,, of NMDAR binding sites (McDonald et al., 1990; Williams et al., 1992) and an increase in the receptor function (Hu and Ticku, unpublished observations) .
In the present study, we examined the hypothesis that upregulation of the NMDAR complex observed after chronic antagonist treatment (Williams et al., 1992) may be attributable to an increase in gene expression of the different subunits composing the NMDARs. To examine this possibility, we measured the mRNA levels for each of the three NMDAR subunits present in the mouse cortical neurons in culture. In addition, using specific antibodies against the Rl and R2AlB polypeptides, we measured the protein levels after NMDAR antagonist treatment.
We found that the Rl subunit polypeptide levels were increased 60-70% after chronic NMDAR antagonist treatment, despite no apparent change in the mRNA levels for the same subunit. We also found that AP-5 treatment increased the R2B mRNA subunit by -45%, whereas the mRNA levels for the other two subunits of the NMDAR (Rl and R2A) were not altered. The increase in the R2B mRNA levels was accompanied by a concomitant larger increase (fivefold) in the levels of the R2A/B polypeptides. These effects were blocked by concomitant exposure of AP-5 with NMDA, or in experiments in which high glutaminecontaining media were used, suggesting that the upregulation was mediated via NMDA receptors, most likely by blocking the tonic activation of the NMDARs. Under our experimental conditions, NMDA alone did not have any effect on the levels of NMDAR polypeptides and did not produce cell death. Because polypeptide levels were not altered, we did not measure the effect of NMDA on mRNA levels. However, it should be pointed out that, depending on the depolarizing conditions, NMDA can up-or downregulate the NMDARs (Bessho et al., 1994; Resink et al., 1995) .
Taken together, our data suggest that the increase in the Rl polypeptide expression, but not in its mRNA, could be determined by a translational or post-translational regulation. It is worth mentioning that in PC12 cells the mRNA encoding the Rl subunit is transcribed, but the correspondent protein is not expressed, suggesting a post-transcriptional control for the expression of the Rl polypeptide (Sucher et al., 1993) . The antagonist-mediated upregulation of the R2A/B subunits is attributable to an increase in their polypeptide levels because of an increase in transcription or mRNA stability and/or a decrease in mRNA turnover. This possibility exists at least for the R2B subunit, because we recently found that the R2A subunit polypeptide is virtually absent in the 'I-d-old cultured neurons that were used in this study, and the expression of this protein increases later during maturation of these neurons in culture (Follesa, unpublished observations). Additional studies are needed to elucidate the potential mechanisms involved in this regulation.
There is no information available about the exact stoichiometry of the NMDAR complex. It has been suggested that the two classes of subunits need to be present in the same NMDAR complex to form functional receptors (Monyer et al., 1992) . Histological and ultrastructural evidence indicates that the Rl and R2A/B proteins are colocalized in many neuronal populations (Petralia et al., 1994) and in the same receptor (Sheng et al., 1994) . Therefore, it is reasonable to assume that when we observed an increase in the number of NMDARs, both classes of subunits, i.e., Rl, and R2, are increased. If so, it is feasible that the relatively small increase in the Rl subunit polypeptide observed in our study may account for the increase in the number of receptors, which is similar to the increase in [1251]MK-801 binding sites (40-80%) (Williams et al., 1992; Follesa, unpublished observations) . With respect to the R2 subunits, it is reasonable to assume that all the R2 polypeptides synthesized are not assembled with the Rl subunit to form functional receptors. This may explain the discrepancy between the relatively small increase in both ['251]MK-801 binding sites and the Rl polypeptide, observed after chronic antagonist exposure, and the larger increase in the R2A/B polypeptides observed in the present study. Immunoprecipitation studies will be undertaken to verify this hypothesis. The NMDAR upregulation has also been observed after chronic ethanol treatment.
It should be noted that, acutely, ethanol also inhibits NMDA responses; however, the mechanism of this action has yet to be elucidated.
The NMDAR binding was increased in vitro and in vivo after chronic ethanol treatment (Grant et al., 1990; Hu and Ticku, 1995) . In addition, chronic ethanol exposure upregulated the NMDAR function (Hu and Ticku, 1995) and gene expression (Hu et al., 1996) of the NMDAR subunits in cultured cortical neurons. It is worth mentioning that other drugs such as ethanol, which produce upregulation of the NMDAR, like the antagonists (this study) also did not alter the mRNA levels for the Rl subunit (Follesa and Ticku, 1995; Hu et al., 1996) despite producing an apparent increase in the Rl polypeptide in the rat hippocampus (Trevisan et al., 1994) and an increase in the Rl and R2 polypeptide after chronic ethanol treatment in mouse cortical neurons (Follesa and Ticku, unpublished observations). This study provides further support to the notion that the Rl gene may be regulated by translational or post-transcriptional mechanisms. In summary, our data suggest that blockade of the glutamatemediated tonic activation of the NMDAR by competitive or noncompetitive antagonists induced upregulation of the NMDAR, because of an increase in mRNA and polypeptides of the different subunits composing the NMDA oligomeric receptor complex in cortical neurons. This raises questions regarding complications that may arise if NMDAR antagonists are used as therapeutic agents to treat pathological conditions associated with excessive glutamate cascade.
